TRPM8, as a member of the transient potential receptor family, has been shown to be highly expressed in androgen-sensitive cancer cells, is a potential prognostic marker for metastatic CRPC, and is also considered a promising druggability target for the treatment of prostate cancer (66). Here, TRPM8 is linked to prostate cancer.